CtDNA-based research exploring how blood-derived copy-number patterns might inform resistance to immune checkpoint therapies in advanced NSCLC, inviting readers to learn about the study design and biomarker comparisons.
Key Takeaways
- CtDNA-based copy-number signatures can be derived from baseline peripheral blood in advanced NSCLC patients
- These copy-number signatures associate with ICI resistance beyond information provided by PD-L1 and TMB
- Study analyzed clinicogenomic correlations including PD-L1, PFS, ORR, and survival outcomes for 37 patients